Document Detail

GH therapy in adult GH deficiency: a review of treatment schedules and the evidence for low starting doses.
MedLine Citation:
PMID:  23152440     Owner:  NLM     Status:  MEDLINE    
Recombinant human GH has been licensed for use in adult patients with GH deficiency (GHD) for over 15 years. Early weight- and surface area-based dosing regimens were effective but resulted in supraphysiological levels of IGF1 and increased incidence of side effects. Current practice has moved towards individualised regimens, starting with low GH doses and gradually titrating the dose according to the level of serum IGF1 to achieve an optimal dose. Here we present the evidence supporting the dosing recommendations of current guidelines and consider factors affecting dose responsiveness and parameters of treatment response. The published data discussed here lend support for the use of low GH dosing regimens in adult GHD. The range of doses defined as 'low dose' in the studies discussed here (∼1-4  mg/week) is in accordance with those recommended in current guidelines and encompasses the dose range recommended by product labels.
Valentina Gasco; Flavia Prodam; Silvia Grottoli; Paolo Marzullo; Salvatore Longobardi; Ezio Ghigo; Gianluca Aimaretti
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-02-20
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  168     ISSN:  1479-683X     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-21     Completed Date:  2013-04-08     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  R55-66     Citation Subset:  IM    
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Dogliotti 14, 10126 Turin, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Dose-Response Relationship, Drug
Drug Interactions
Drug Monitoring
Evidence-Based Medicine*
Hormone Replacement Therapy* / adverse effects
Human Growth Hormone / administration & dosage,  adverse effects,  deficiency*,  therapeutic use*
Individualized Medicine
Insulin-Like Growth Factor I / analysis
Obesity / complications
Recombinant Proteins / administration & dosage,  adverse effects,  therapeutic use
Sex Characteristics
Reg. No./Substance:
0/Recombinant Proteins; 12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroid...
Next Document:  Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopath...